Literature DB >> 17932493

HIV drug development: the next 25 years.

Charles Flexner1.   

Abstract

The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932493     DOI: 10.1038/nrd2336

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  87 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

Review 2.  Targeting frameshifting in the human immunodeficiency virus.

Authors:  Léa Brakier-Gingras; Johanie Charbonneau; Samuel E Butcher
Journal:  Expert Opin Ther Targets       Date:  2012-03       Impact factor: 6.902

3.  Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.

Authors:  Supachai Sakkhachornphop; Carlos F Barbas; Rassamee Keawvichit; Kanlaya Wongworapat; Chatchai Tayapiwatana
Journal:  Hum Gene Ther       Date:  2012-05-08       Impact factor: 5.695

4.  Strategies for recognition of stem-loop RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence.

Authors:  Prakash B Palde; Leslie O Ofori; Peter C Gareiss; Jaclyn Lerea; Benjamin L Miller
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

Review 5.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

Review 6.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo.

Authors:  Paul S Marinec; Lei Chen; Kenneth J Barr; Mitchell W Mutz; Gerald R Crabtree; Jason E Gestwicki
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

Review 8.  Clinically relevant drug-drug interactions between antiretrovirals and antifungals.

Authors:  Ramya Krishna Vadlapatla; Mitesh Patel; Durga K Paturi; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-02-12       Impact factor: 4.481

9.  Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication.

Authors:  Frederico Aires da Silva; Min Li; Sylvie Rato; Sara Maia; Rui Malhó; Kylie Warren; David Harrich; Robert Craigie; Carlos Barbas; Joao Goncalves
Journal:  Biotechnol Appl Biochem       Date:  2012-10-10       Impact factor: 2.431

Review 10.  The same but different: autologous hematopoietic stem cell transplantation for patients with lymphoma and HIV infection.

Authors:  R F Ambinder
Journal:  Bone Marrow Transplant       Date:  2009-05-18       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.